A new injectable solution that self-assembles into a hydrogel under the right conditions could help manage HIV differently from any currently available methods, researchers report.
The gel releases a steady dose of the anti-HIV drug lamivudine over six weeks, which suggests that people living with HIV could have new therapy that doesn’t require a daily pill regimen to prevent AIDS.
“The primary challenge in HIV treatment is the need for lifelong management of the virus, and one way to address this is to reduce dosing frequencies to help patients stick to medical regimens,” says Honggang Cui, a chemical and biomolecular engineer at Johns Hopkins University who led the research. “This new molecular design shows us a future in which drug hydrogelation can do that to improve HIV treatment.”
The research appears in the Journal of the American Chemical Society.
Cui’s team demonstrated in test tubes simulating the conditions of plasma, the liquid portion of blood, that the gel quickly separates into molecules of lamivudine. By injecting the gel in the backs of mice, the researchers found one injection was sufficient to maintain effective and lasting drug concentrations for 42 days with nearly no side effects.
“Our goal is to help improve people’s quality of life,” Cui says. “The antiviral substance can be injected under the skin and remain in place over an extended period, releasing the therapeutic compound slowly and consistently—a critical need for individuals with HIV.”
For people living with HIV, the key is maintaining bloodstream drug levels at concentrations that suppress virus load in the body. But that can be difficult with traditional approaches because the body naturally rids itself of these chemicals, Cui says, which is why different treatments require different dosages and dosing frequencies to work.
The researchers plan to continue testing their work with medications used in combination therapies along with lamivudine, as most of these treatments involve a cocktail of two or more drugs.
Because lamivudine is an FDA-approved drug to treat HIV and hepatitis B, the researchers say the hydrogel could also help manage hepatitis B.
“This is a novel way to deliver anti-HIV meds, and this platform has the advantage that a single polymer can be programmed to deliver several different drugs simultaneously,” says coauthor Charles W. Flexner, a professor of medicine, pharmacology, and molecular sciences in the Johns Hopkins School of Medicine.
“One of the drawbacks of the approved injectable HIV treatments is that none have activity against hepatitis B virus, which is a common co-infection with HIV, especially in Asia and Africa. This formulation delivers lamivudine, a drug active against both HIV and HBV, but can also be modified to deliver tenofovir, which is the current standard of care for HBV treatment.”
In the long term, the team envisions their hydrogel working as a preventive measure, similar to how some people take anti-HIV drugs to avoid infection.
“Keeping the high drug levels in plasma for 42 days is very impressive,” Cui says. “But in the future, we hope it will be even longer.”
Hydrogels have unique water-absorbing properties that give them a jellylike consistency resembling biological tissue. The new gel undergoes self-formulation, stays close to the site of injection, and separates into molecules that can fend off the virus without the need for additional carriers or delivery materials.
“The most exciting aspect of these gel filaments is that they consist entirely of the therapeutic agent itself,” Cui says. “Everything originates from the same compound after injection, and this simplest drug formulation could streamline the regulatory approval process once clinical efficacy is demonstrated.”
The team tweaked the molecular properties of lamivudine to act as the building blocks of a supramolecular polymer, a large chain of repeating molecules that can either stick together tightly or come apart, depending on temperature, pH, and other external conditions.
Source: Johns Hopkins University
